Last updated on March 2020

A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065

Brief description of study

The purpose of this study is to evaluate safety and efficacy of risankizumab in subjects with ulcerative colitis (UC) in subjects who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC.

This study consists of three sub-studies: Substudy 1 is a 52-week, randomized, double-blind, placebo-controlled maintenance study; Substudy 2 is 52-week, randomized, exploratory maintenance study; and Substudy 3 is an open-label long-term extension study for subjects who completed Substudy 1 or 2.

Clinical Study Identifier: NCT03398135

Find a site near you

Start Over

Ucsd /Id# 160430

La Jolla, CA United States
  Connect »

Advanced Research Institute /ID# 161945

New Port Richey, FL United States
  Connect »

Indiana University /ID# 167250

Indianapolis, IN United States
  Connect »

Delricht Research /ID# 206817

New Orleans, LA United States
  Connect »

Gastro One /ID# 160373

Germantown, TN United States
  Connect »

Sagact Pllc /Id# 168774

San Antonio, TX United States
  Connect »

Cemic /Id# 167805

Buenos Aires, Argentina
  Connect »

Sanatorio 9 de Julio S.A. /ID# 167803

San Miguel de Tucuman, Argentina
  Connect »

UZ Brussels /ID# 164175

Jette, Brussels, Belgium
  Connect »

PMI Euromedservice /ID# 204918

Pushkin, Russian Federation
  Connect »

City Clinical Hospital #40 /ID# 204927

St. Petersburg, Russian Federation
  Connect »

Dr JP Wright /ID# 171142

Cape Town, South Africa
  Connect »